CJC-1295 vs Ipamorelin — receptors, half-life, why paired
CJC-1295 and Ipamorelin are the two peptides most often named together when growth-hormone-secretagogue research comes up — and they are routinely assumed to be two flavours of the same thing. They are not. They act on two different receptors, they have wildly different half-lives, and they do two different jobs in the same circuit. This is a research-first comparison of what each compound is, what the literature actually supports, and why the honest answer to “which one” is usually “they are studied together, not chosen between.”
The two compounds at a glance
- CJC-1295 — a 30-residue synthetic analogue of GHRH(1-29) with substitutions for protease resistance and, in the DAC form, a maleimidopropionamide-lysine group that covalently binds plasma albumin. Receptor: GHRH receptor (G(s)-coupled, cAMP). Kinetics: long-acting in the DAC form (~8 days). Role: raises the baseline / amplitude of GH release. Standalone context: CJC-1295 + Ipamorelin synopsis.
- Ipamorelin — a 5-residue pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2). Receptor: GHS-R1a, the ghrelin receptor (G(q)-coupled, phospholipase C / calcium). Kinetics: short-acting, producing a discrete GH pulse. Role: fires the pulse, with notable selectivity (no cortisol / prolactin rise). Product page: Ipamorelin 5 mg.
What the CJC-1295 research shows
CJC-1295 is the long-acting GHRH side of the pairing. The defining piece of biochemistry is the albumin bioconjugation: the Jetté 2005 paper in Endocrinology established CJC-1295 as an hGRF(1-29)-albumin bioconjugate in which a reactive maleimidopropionamide group forms a covalent bond with circulating albumin, and showed that this covalent binding is what converts a peptide with a minutes-long half-life into one that circulates for days [1]. The practical consequence appears in the human pharmacokinetic work: the Teichman 2006 study in the Journal of Clinical Endocrinology & Metabolism reported that a single subcutaneous dose of CJC-1295 in healthy adults produced dose-dependent elevations in GH for roughly six days and in IGF-1 for nine to eleven days, with an estimated half-life of 5.8–8.1 days, and was well tolerated across the 30–60 µg/kg range tested [2].
The mechanistic point is that this is a baselineeffect. By keeping GHRH-receptor signalling elevated over a multi-day window, CJC-1295 raises the readiness of the pituitary to release GH and lifts the amplitude of the pulses that occur — it does not, by itself, manufacture sharp on-demand peaks. The caveat: the human record stops at early pharmacokinetic and GH/IGF-1-pulsatility studies; there are no published phase-2 trials with downstream endpoints, and CJC-1295 was never FDA-approved.
What the Ipamorelin research shows
Ipamorelin is the acute-pulse side. The foundational 1998 paper by Raun and colleagues in the European Journal of Endocrinology characterised Ipamorelin as the first selective growth-hormone secretagogue: it produced potent GH release comparable to the older GHRP-6, but — critically — without the increases in ACTH and cortisol seen with that earlier class [3]. That selectivity is the headline. Ipamorelin works through the GHS-R1a receptor (the ghrelin receptor) on pituitary somatotroph cells, and its short action produces a discrete GH pulse rather than a sustained shift.
The cleanest way to keep them straight: CJC-1295 reads outward from a GHRH-receptor, days-long baseline story; Ipamorelin reads outward from a ghrelin-receptor, minutes-long, selective pulse story. Same circuit, two different jobs.
On the development record: Ipamorelin advanced further through clinical study than CJC-1295 — a phase-2 program targeting post-operative ileus reached interim readouts — but that program was discontinued, so Ipamorelin too remains a research-grade compound rather than an approved medicine.
How they actually differ
- Receptor. CJC-1295 is a GHRH analogue acting on the GHRH receptor; Ipamorelin is a ghrelin-mimetic acting on GHS-R1a. Different receptors, different downstream signalling (cAMP vs phospholipase C / calcium).
- Half-life. CJC-1295 in the DAC form is long-acting (~8 days of sustained GH/IGF-1 elevation in the human pharmacokinetic data); Ipamorelin is short-acting and produces a sharp, transient pulse.
- Functional role. CJC-1295 raises the baseline / amplitude of endogenous GH release; Ipamorelin triggers a discrete pulse. One sets the floor, the other fires the spike.
- Selectivity. Ipamorelin releases GH without the cortisol / prolactin elevations that limited older GHRPs — the property that made it the cleaner research tool of its class. (Selectivity is a defining trait of the ghrelin-mimetic, not of the GHRH analogue.)
- The DAC footnote on CJC-1295. “CJC-1295 with DAC” carries the albumin-binding group and lasts days; “CJC-1295 without DAC” (also sold as Modified GRF(1-29)) omits it and reverts to a ~30-minute half-life. Same parent sequence, very different kinetics — so the form matters as much as the name.
Why paired, not chosen between
Because the two compounds occupy different receptors and do different jobs, the research literature treats them as complementary rather than as alternatives. The somatotropic axis is driven by two parallel upstream signals — GHRH (which sets baseline readiness) and ghrelin (which produces release on demand). CJC-1295 stands in for the first; Ipamorelin stands in for the second. Activating both at once engages two parallel pathways in the same somatotroph cells, and the GH release observed from co-administration in animal models is larger than the sum of the two compounds tested separately — a synergy that follows directly from the receptor logic, not from marketing.
That is why the practical research format is a paired one. The combined CJC-1295 + Ipamorelin blend exists alongside the standalone Ipamorelin 5 mg vial precisely because the two are studied together. Choosing one over the other discards half the mechanism; pairing them models the natural pulsatile rhythm more closely than either alone. For the deeper receptor-pharmacology treatment and the dosing-research context, see the cluster’s mechanism synopsis and dosing-research protocols.
An honest verdict
If forced to frame it as “which,” the honest research answer is that the question is mostly the wrong one. CJC-1295 and Ipamorelin are not competing tools that do the same thing better or worse — they are two halves of one circuit. A GHRH analogue without a secretagogue raises the baseline but leaves the pulse muted; a secretagogue without an elevated baseline fires a smaller spike. The pairing is one of the cleaner receptor-pharmacology stories in the research-peptide category: two defined targets, complementary roles, and a synergy that holds up in animal models.
The limits are equally honest. The synergy and the pulsatility endpoints rest on animal pharmacology and cell-based receptor work; controlled human trials of the pairinghave not been published, and both compounds’ formal development programs ended before clinical endpoints were established. CJC-1295 was never FDA-approved; Ipamorelin’s phase-2 program was discontinued. Both remain research-grade. Whatever a label or a forum thread implies, the published evidence is about GH and IGF-1 release and pulsatility — nothing downstream of that has been demonstrated in controlled human study.
Related in this cluster
- Parent synopsis: CJC-1295 + Ipamorelin — the GHRH/GHRP pairing.
- Mechanism deep-dive: CJC-1295 + Ipamorelin mechanism research.
- Dosing-research context: CJC-1295 + Ipamorelin dosing-research protocols.
- GHRH-class context: Tesamorelin vs other GHRH analogues and Tesamorelin vs CJC-1295.
- Category overview: research peptides in the UAE.
Further reading
Peer-reviewed citations used inline:
- [1] Jetté et al. — Endocrinology 2005. hGRF(1-29)-albumin bioconjugate (CJC-1295): covalent albumin binding underlies the multi-day half-life. DOI 10.1210/en.2004-1286.
- [2] Teichman et al. — J Clin Endocrinol Metab 2006. Single SC CJC-1295 in healthy adults: dose-dependent GH rises ~6+ days, IGF-1 rises 9-11 days, estimated half-life 5.8-8.1 days, well tolerated at 30-60 µg/kg. DOI 10.1210/jc.2005-1536.
- [3] Raun et al. — Eur J Endocrinol 1998. Ipamorelin, the first selective GH secretagogue: potent GH release with no ACTH / cortisol increase. DOI 10.1530/eje.0.1390552.
Last reviewed 12 June 2026. Wellness Labs supplies Ipamorelin 5 mg and CJC-1295 + Ipamorelin paired blends as research-grade lyophilised powder for non-clinical investigation. Editorial inbox: info@uaewellnesslab.com.
Frequently asked questions
- What is the difference between CJC-1295 and Ipamorelin?
- CJC-1295 and Ipamorelin act on two different receptors and play two different roles in the same growth-hormone circuit. CJC-1295 is a synthetic GHRH analogue that works through the GHRH receptor; in its albumin-binding DAC form it is long-acting (roughly an eight-day half-life in human pharmacokinetic studies) and raises the baseline amplitude of endogenous GH release. Ipamorelin is a short-acting selective agonist of the GHS-R1a ghrelin receptor that triggers a discrete, sharp GH pulse. In short, CJC-1295 sets the baseline while Ipamorelin fires the pulse. Both are research-grade compounds studied for GH and IGF-1 release; neither is an approved medicine.
- Is CJC-1295 or Ipamorelin better?
- In a research context, "better" is usually the wrong framing because the two compounds are not substitutes that do the same job. CJC-1295 is a GHRH analogue that raises the baseline of endogenous GH release over a sustained window, while Ipamorelin is a ghrelin-mimetic that produces an acute, selective GH pulse. They occupy different receptors and complement each other rather than compete. The published evidence covers GH and IGF-1 release and pulsatility, and rests largely on animal pharmacology and early human studies; controlled human trials of the pairing have not been published. Both remain research-grade compounds for non-clinical investigation, not approved medicines.
- Why are CJC-1295 and Ipamorelin used together?
- They are studied together because they engage two parallel signals that both feed endogenous growth-hormone release. The somatotropic axis is driven by GHRH, which sets the pituitary baseline, and by ghrelin, which produces release on demand. CJC-1295 stands in for the first and Ipamorelin for the second, so activating both engages two complementary pathways in the same pituitary cells. In animal models, co-administration produces GH release larger than the sum of either compound alone, which follows from the receptor logic. This complementarity is why the research literature pairs them rather than choosing between them. Both are research-grade and not approved medicines.
- What is CJC-1295 with DAC versus without DAC?
- The difference is the albumin-binding modification and therefore the half-life. CJC-1295 with DAC carries a maleimidopropionamide-lysine group that covalently binds circulating albumin, converting a peptide with a minutes-long half-life into one that persists for roughly eight days and sustains GH and IGF-1 elevation over a multi-day window. CJC-1295 without DAC, also sold as Modified GRF(1-29), omits that group and reverts to a half-life of about thirty minutes. The parent sequence is the same, but the kinetics are very different, so the form on the label matters as much as the name. Both forms are research-grade compounds, not approved medicines.
- Does Ipamorelin raise cortisol?
- A defining feature of Ipamorelin in the research literature is that it does not. It was characterised as the first selective growth-hormone secretagogue, producing GH release comparable to the older GHRP-6 but without the increases in ACTH and cortisol that accompanied that earlier class, and without driving up prolactin at GH-releasing doses. That selectivity is the main reason it is regarded as the cleaner research tool among ghrelin-mimetics, since it triggers a GH pulse through the GHS-R1a receptor without the off-target hormonal rises seen with less selective compounds. This describes its profile in published research only; Ipamorelin remains a research-grade compound for non-clinical investigation and is not an approved medicine.